Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Gets FDA Clearance for Transplant Dx System

NEW YORK (GenomeWeb News) – Invitrogen said after the close of the market on Tuesday that it has received US Food and Drug Administration clearance to sell its new transplant diagnostics system.
The Carlsbad, Calif.-based firm received 510(k) clearance for its DynaChip Antibody Analysis System, an automated chip-based system for human leukocyte antibody detection and identification. The tests are run on protein arrays developed by the company.
“The high capacity of the DynaChip allows us to add a larger number of proteins than competitive products, reducing the amount of testing and overall turn-around time,” Jim Janicki, VP and GM of Invitrogen’s Applied Markets business unit, said in a statement.
The DynaChip system is the first Class II IVD product for which Invitrogen has received FDA 510(k) clearance. Invitrogen CEO said during the firm’s first-quarter conference call in April that the firm expected clearance for the system during spring.
However, the transplant diagnostic system is not Invitrogen’s first entry into the diagnostics field. In addition to supplying in vitro diagnostic partners with reagents that are used in commercialized kits, the firm currently sells an HER2 chromogenic in situ hybridization diagnostic kit outside of the US and is currently awaiting FDA clearance for the kit in the US.
As reported last week by GenomeWeb Daily News, Invitrogen expects to use the new diagnostics system as the base for developing additional diagnostic applications and assays.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.